Durvalumab vs Hepatitis B Virus Hbsag Surface Protein Antigen

Durvalumab vs Hepatitis B Virus Hbsag Surface Protein Antigen: Overview

This comparison examines the pharmacological differences between Durvalumab and Hepatitis B Virus Hbsag Surface Protein Antigen.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Durvalumab — 17 days.

Chemical Properties

Type: Durvalumab — Antibody; Hepatitis B Virus Hbsag Surface Protein Antigen — Vaccine component.